G1 Therapeutics, Inc.
GTHX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $82,511 | $51,301 | $31,476 | $45,285 |
| % Growth | 60.8% | 63% | -30.5% | – |
| Cost of Goods Sold | $7,195 | $3,748 | $2,016 | $0 |
| Gross Profit | $75,316 | $47,553 | $29,460 | $45,285 |
| % Margin | 91.3% | 92.7% | 93.6% | 100% |
| R&D Expenses | $43,711 | $83,316 | $76,225 | $73,271 |
| G&A Expenses | $0 | $0 | $0 | $68,490 |
| SG&A Expenses | $71,132 | $100,415 | $95,692 | $68,490 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $3 | -$346 | -$542 |
| Operating Expenses | $114,843 | $183,731 | $171,917 | $141,761 |
| Operating Income | -$39,527 | -$136,178 | -$142,457 | -$96,476 |
| % Margin | -47.9% | -265.4% | -452.6% | -213% |
| Other Income/Exp. Net | -$5,325 | -$9,681 | -$4,970 | -$1,368 |
| Pre-Tax Income | -$44,852 | -$145,859 | -$147,427 | -$97,844 |
| Tax Expense | $3,115 | $1,700 | $925 | $1,410 |
| Net Income | -$47,967 | -$147,559 | -$148,352 | -$99,254 |
| % Margin | -58.1% | -287.6% | -471.3% | -219.2% |
| EPS | -0.93 | -3.38 | -3.54 | -2.62 |
| % Growth | 72.5% | 4.5% | -35.1% | – |
| EPS Diluted | -0.93 | -3.38 | -3.54 | -2.62 |
| Weighted Avg Shares Out | 51,733 | 43,626 | 41,943 | 37,878 |
| Weighted Avg Shares Out Dil | 51,733 | 43,626 | 41,943 | 37,878 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,473 | $748 | $43 | $952 |
| Interest Expense | $10,038 | $10,432 | $4,667 | $1,778 |
| Depreciation & Amortization | $513 | $530 | $469 | $582 |
| EBITDA | -$34,301 | -$134,897 | -$142,457 | -$95,484 |
| % Margin | -41.6% | -263% | -452.6% | -210.9% |